01 Rising Adoption of Liquid Handling Systems Automated liquid handling systems are multifunctional devices made for the sampling, combining, and mixing liquid samples in laboratories. These systems help eliminate errors and sample contamination and reduce the manual work of lab technicians by performing multiple laboratory tasks. In addition, liquid handling plays a vital role in many experiments related to life science, particularly in genomic and proteomic research. Moreover, key market players are developing compact and user-friendly liquid-handling workstations that can operate in small-and mid-level laboratories. For instance, in February 2018, Tecan Group Limited introduced the Fluent Gx automation workstation designed to meet the stringent needs of clinical and regulated laboratories.Furthermore, the rising demand for early detection of diseases and growing demand for treatment of various chronic and life-threatening illnesses is driving the adoption of automated liquid handling systems by diagnostic centers and hospitals. Thus, the rise in the adoption of liquid handling systems across small- to large-scale research laboratories for various sample handling requirements is expected to propel the expansion of this market during the forecast period.
02 Increasing Prevalence of Cancer and Other Chronic Diseases The development of newer, more potent medications is necessary due to the increased incidence of cancer and other chronic diseases. Global society was significantly impacted by cancer. For instance, 1,735,350 new cases of cancer were reported in the US in 2018, according to the National Cancer Institute. Also, the World Health Organization (WHO) says that about 3.7 million new cancer cases are found annually in Europe.In addition, according to the National Institute of Cancer Prevention and Research (NICPR), in 2018, the estimated number of people diagnosed with cancer was around 2.25 million in India. This rise in cancer and other chronic disorders, such as HIV, tuberculosis, etc., drives market growth as automated cell culture helps understand the mechanism and cause of these diseases. Additionally, automated cell culture helps in the research and development of drugs. It improves patients' health and quality of life from dangerous diseases such as cancer and genetic disorders.
01 High Maintenance Cost Research laboratories and organizations must make massive investments to maintain automated cell culture. Moreover, stringent manufacturing regulations for market approvals of the equipment by various governmental agencies, such as the US Food and Drug Administration (FDA) and the European Commission, increase the costs of these systems. Furthermore, integrating information technology (IT) in instruments for laboratory automation requires high manufacturing expenses, leading to elevated equipment prices. The high initial and maintenance cost of automated cell culture is expected to hamper the growth of the global market as small-scale research laboratories and organizations find it unaffordable to procure such expensive equipment. Moreover, the need for more awareness and the shortage of skilled professionals are expected to hinder market growth during the assessment period.
01 Growing Focus on Regenerative Medicine Regenerative medicine is a young branch of medicine that aims to provide treatments for the replacement of organ/tissue systems in the human body. Regenerative medicine utilizes cells, biomaterials, and molecules to fix structures in the body that are damaged due to injury or disease. Cell therapies and regenerative medicine represent an enormous potential to improve the health-related quality of life of many chronic-ill patients. The imminent and expanding need for novel therapies to solve debilitating health conditions is driving manufacturers to develop innovative cell culture systems.The technological advancements in automated cell culture offer enhanced productivity and quality of cell lines. Moreover, increasing players' participation in regenerative medicine drives the demand for automated cell culture systems. For instance, Hitachi announced the commercialization of the automated cell mass culture for the first time in Japan, which can manufacture commercial induced pluripotent stem cells (iPS) for regenerative medicine in April 2017. The rising need for novel therapies and the development of robotic cell culture workstations and cell detection devices is, in turn, creating opportunities for the automated cell culture market.
June 2026 Thermo Fisher Scientific expanded its automated cell culture portfolio with next-generation robotic cell processing systems supporting advanced cell therapy manufacturing.
April 2026 Sartorius launched an advanced automated cell culture platform designed to improve scalability, reproducibility and process efficiency in biopharmaceutical production.
February 2026 Cytiva expanded its automated cell culture technologies through new integrated bioprocessing solutions supporting cell and gene therapy manufacturing.
November 2025 Eppendorf introduced an automated cell culture workflow solution integrating incubation, liquid handling and real-time process monitoring for laboratory automation.
July 2025 Beckman Coulter Life Sciences expanded its laboratory automation portfolio with new automated cell culture solutions designed to improve high-throughput research and biomanufacturing workflows.